Literature DB >> 30764894

High circ_100053 predicts a poor outcome for chronic myeloid leukemia and is involved in imatinib resistance.

Lei Ping1, Chen Jian-Jun2, Liao Chu-Shu1, Liu Guang-Hua1, Zhou Ming2.   

Abstract

Chronic myeloid leukemia (CML) is a rare clonal myeloproliferative malignancy, which is caused by a reciprocal translocation between chromosomes 9 and 22 t(9;22) (q34;q11). Altered circle RNAs (circRNAs) could contribute to leukemogenesis. In this study, we aimed to investigate the expression profiling of circRNAs in CML. We performed circRNA-sequencing to identify differentially expressed circRNAs in CML cells. Furthermore, we found that circ_100053 was significantly upregulated in peripheral blood mononuclear cells (PBMC) and serum samples from CML compared with healthy controls. CircRNA_100053 expression was associated with clinical stage (p=0.037) and BCR/ABL mutant status (p=0.008). High circ_100053 expression predicted a poor outcome of CML patients and imatinib resistance, suggesting the putative role of circ_100053 as an CML biomarker. Our findings provide insights on circRNAs expression in the development and treatment of CML.

Entities:  

Year:  2019        PMID: 30764894     DOI: 10.3727/096504018X15412701483326

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  14 in total

Review 1.  Tip of the iceberg: roles of circRNAs in hematological malignancies.

Authors:  Shan-Shan Guo; Bi-Xia Li; Duo-Bing Zou; Shu-Jun Yang; Li-Xia Sheng; Gui-Fang Ouyang; Qi-Tian Mu; He Huang
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

Review 2.  Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance.

Authors:  Ajaz A Bhat; Salma N Younes; Syed Shadab Raza; Lubna Zarif; Sabah Nisar; Ikhlak Ahmed; Rashid Mir; Sachin Kumar; Surender K Sharawat; Sheema Hashem; Imadeldin Elfaki; Michal Kulinski; Shilpa Kuttikrishnan; Kirti S Prabhu; Abdul Q Khan; Santosh K Yadav; Wael El-Rifai; Mohammad A Zargar; Hatem Zayed; Mohammad Haris; Shahab Uddin
Journal:  Mol Cancer       Date:  2020-03-12       Impact factor: 27.401

Review 3.  The functions and clinical significance of circRNAs in hematological malignancies.

Authors:  Xiangxiang Zhou; Linquan Zhan; Kai Huang; Xin Wang
Journal:  J Hematol Oncol       Date:  2020-10-17       Impact factor: 17.388

4.  CircBA1 derived from BCR-ABL fusion gene inhibits cell proliferation in chronic myeloid leukemia.

Authors:  Jin Wang; Hu-Lin Ma; Wen-Rong Liu; Yong Peng; Jian-Kang Zhou; Jin-Lin Yang
Journal:  Cancer Commun (Lond)       Date:  2021-01-14

Review 5.  Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance.

Authors:  Chaochu Cui; Jianbo Yang; Xiao Li; Dongling Liu; Liwu Fu; Xianwei Wang
Journal:  Mol Cancer       Date:  2020-03-14       Impact factor: 27.401

Review 6.  Biological Roles and Mechanisms of Circular RNA in Human Cancers.

Authors:  Qing Tang; Swei Sunny Hann
Journal:  Onco Targets Ther       Date:  2020-03-09       Impact factor: 4.147

Review 7.  Circular RNAs: Emerging Role in Cancer Diagnostics and Therapeutics.

Authors:  Anuva Rajappa; Sucharita Banerjee; Vivek Sharma; Piyush Khandelia
Journal:  Front Mol Biosci       Date:  2020-10-28

8.  circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway.

Authors:  Yutang Huang; Yi Dai; Chunjie Wen; Shuai He; Jingjing Shi; Dezhang Zhao; Lanxiang Wu; Honghao Zhou
Journal:  Mol Ther Nucleic Acids       Date:  2020-07-25       Impact factor: 8.886

Review 9.  CircRNAs: biogenesis, functions, and role in drug-resistant Tumours.

Authors:  Shuo Ma; Shan Kong; Feng Wang; Shaoqing Ju
Journal:  Mol Cancer       Date:  2020-08-05       Impact factor: 27.401

Review 10.  CircRNAs in anticancer drug resistance: recent advances and future potential.

Authors:  Tianwei Xu; Mengwei Wang; Lihua Jiang; Li Ma; Li Wan; Qinnan Chen; Chenchen Wei; Zhaoxia Wang
Journal:  Mol Cancer       Date:  2020-08-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.